ELI LILLY & Co — fact timeline

ELI LILLY & Co shareholders rejected Shareholder proposal to prepare an annual lobbying report at the 2026-05-04 meeting.

“By the following vote, a shareholder proposal to prepare an annual lobbying report was not approved:”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting adoption of a policy and bylaw amendment to require an independent board chair at the 2026-05-04 meeting.

“By the following vote, a shareholder proposal requesting the adoption of a policy and amendment to the bylaws to require an independent board chair was not approved:”

ELI LILLY & Co shareholders rejected Amend Articles of Incorporation to eliminate supermajority voting provisions at the 2026-05-04 meeting.

“The proposal to amend the Articles to eliminate supermajority voting provisions did not receive the required vote of 80% of outstanding shares.”

ELI LILLY & Co shareholders rejected Amend Articles of Incorporation to eliminate classified board structure at the 2026-05-04 meeting.

“The proposal to amend the Company's Articles of Incorporation (the “Articles”) to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares.”

ELI LILLY & Co shareholders approved Ratification of appointment of Ernst & Young LLP as independent auditor for 2026 at the 2026-05-04 meeting.

“The appointment of Ernst & Young LLP as the Company's independent auditor for 2026 was ratified by the following shareholder vote:”

ELI LILLY & Co shareholders approved Advisory approval of compensation paid to named executive officers at the 2026-05-04 meeting.

“By the following vote, the shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers:”

ELI LILLY & Co shareholders approved Election of four nominees for director to serve three-year terms ending at the 2029 annual meeting at the 2026-05-04 meeting.

“The four nominees for director were elected to serve three-year terms ending at the Company's annual meeting of shareholders in 2029, as follows:”

ELI LILLY & Co reported FY 2026 results: revenue 82.0 billion to 85.0 billion, EPS 35.50 to 37.00. Guidance raised.

“Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.”

ELI LILLY & Co reported Q1 2026 results: revenue 19,799, net income 7,396, EPS 8.26.

“Revenue $ 19,799 $ 12,729 56% Net income – Reported 7,396 2,759 168% Earnings per share – Reported 8.26 3.06 170%”

Karen Walker resigned as Director at ELI LILLY & Co.

“Karen Walker notified the Board of her resignation from the Board effective December 31, 2024.”

Lucas Montarce was elected as executive vice president and chief financial officer at ELI LILLY & Co.

“elected Lucas Montarce, age 47, as executive vice president and chief financial officer”

Marschall S. Runge retired as Director at ELI LILLY & Co.

“On August 13, 2024, Dr. Marschall S. Runge notified the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") of his decision to retire from the Board, effective as of August 31, 2024.”

Gordon Brooks was appointed as interim chief financial officer at ELI LILLY & Co.

“Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company.”

Anat Ashkenazi resigned as executive vice president and chief financial officer at ELI LILLY & Co.

“On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.”

Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer at ELI LILLY & Co.

“Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.”

ELI LILLY & Co shareholders rejected Shareholder proposal for Company to adopt a comprehensive human rights policy at the 2024-05-06 meeting.

“By the following vote, a shareholder proposal for the Company to adopt a comprehensive human rights policy was not approved: For Against Abstain Broker Nonvote 77,058,700 691,658,094 5,698,325 82,256,109”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting to establish and report on a process by which impact of extended patent exclusivities on product access would be considered at the 2024-05-06 meeting.

“By the following vote, a shareholder proposal requesting to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents was not approved: For Against Abstain Broker Nonvote 68,370,561 699,538,270 6,506,288 82,256,109”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting report on effectiveness of diversity, equity, and inclusion efforts at the 2024-05-06 meeting.

“By the following vote, a shareholder proposal requesting a report on the effectiveness of the Company's diversity, equity, and inclusion efforts was not approved: For Against Abstain Broker Nonvote 183,128,839 586,886,679 4,399,601 82,256,109”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting publication of annual report disclosing lobbying activities at the 2024-05-06 meeting.

“By the following vote, a shareholder proposal requesting publication of an annual report disclosing lobbying activities was not approved: For Against Abstain Broker Nonvote 194,184,250 567,382,406 12,848,463 82,256,109”

ELI LILLY & Co shareholders rejected Amend Articles of Incorporation to eliminate supermajority voting provisions at the 2024-05-06 meeting.

“The proposal to amend the Articles to eliminate supermajority voting provisions did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows: For Against Abstain Broker Nonvote 665,237,870 108,058,286 1,118,963 82,256,109”

ELI LILLY & Co shareholders rejected Amend Articles of Incorporation to eliminate classified board structure at the 2024-05-06 meeting.

“The proposal to amend the Company's Articles of Incorporation (the “Articles”) to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows: For Against Abstain Broker Nonvote 666,456,836 106,518,999 1,439,284 82,256,109”

ELI LILLY & Co shareholders approved Ratification of Ernst & Young LLP as independent auditor for 2024 at the 2024-05-06 meeting.

“The appointment of Ernst & Young LLP as the Company's independent auditor for 2024 was ratified by the following shareholder vote: For Against Abstain 819,656,263 35,914,315 1,100,650”

ELI LILLY & Co shareholders approved Advisory approval of compensation paid to named executive officers at the 2024-05-06 meeting.

“By the following vote, the shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers: For Against Abstain Broker Nonvote 734,022,954 38,576,757 1,815,408 82,256,109”

ELI LILLY & Co shareholders approved Election of four nominees for director to serve three-year terms ending in 2027 at the 2024-05-06 meeting.

“The four nominees for director were elected to serve three-year terms ending at the Company's annual meeting of shareholders in 2027, as follows: Nominee For Against Abstain Broker Nonvote Katherine Baicker, Ph.D. 768,750,015 4,790,679 874,425 82,256,109 J. Erik Fyrwald 707,022,149 66,489,475 903,495 82,256,109 Jamere Jackson 756,573,062 16,842,872 999,185 82,256,109 Gabrielle Sulzberger 758,868,317 14,553,438 993,364 82,256,109”

ELI LILLY & Co reported first quarter of 2024 results: revenue $8,768.0, net income $2,242.9, EPS $2.48. Guidance raised.

“on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data First Quarter 2024 2023 % Change Revenue $ 8,768.0 $ 6,960.0 26% Net income – Reported 2,242.9 1,344.9 67% Earnings per share – Reported 2.48 1.49 66% Net income – Non-GAAP 2,335.3 1,463.9 60% Earnings per share – Non-GAAP 2.58”

ELI LILLY & Co reported the quarter and year ended December 31, 2023 results: revenue $9,353.4, net income 2,189.6, EPS 2.42. Guidance initiated.

“on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Fourth Quarter 2023 2022 % Change Revenue $ 9,353.4 $ 7,301.8 28% Net income – Reported 2,189.6 1,937.7 13% Earnings per share – Reported 2.42 2.14 13% Net income – Non-GAAP 2,249.4 1,893.1 19% Earnings per share – Non-GAAP 2.49”

ELI LILLY & Co reported the third quarter of 2023 results: revenue $9,498.6, net income $(57.4), EPS $(0.06).

“Revenue $9,498.6 $6,941.6 37% Net income (loss) – Reported (57.4) 1,451.7 NM Earnings (loss) per share – Reported (0.06) 1.61 NM”

ELI LILLY & Co reported the second quarter of 2023 results: revenue $8,312.1, net income $1,763.2, EPS $1.95. Guidance raised.

“on important public announcements, visit the news section of Lilly's website. 2 Financial Results $ in millions, except per share data Second Quarter 2023 2022 % Change Revenue $8,312.1 $6,488.0 28% Net Income – Reported 1,763.2 952.5 85% EPS – Reported 1.95 1.05 86% Net Income – Non-GAAP 1,904.4 1,131.3 68% EPS – Non-GAAP 2.11 1.25 69% A discussion of the”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting a report on the effectiveness of the Company's diversity, equity, and inclusion efforts. at the 2023-05-01 meeting.

“By the following vote, a shareholder proposal requesting a report on the effectiveness of the Company's diversity, equity, and inclusion efforts was not approved:”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting to publish a third-party review of lobbying activities and alignment with public policy positions and statements. at the 2023-05-01 meeting.

“By the following vote, a shareholder proposal requesting to publish a third-party review of lobbying activities and alignment with public policy positions and statements was not approved:”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting a report on risks of supporting abortion. at the 2023-05-01 meeting.

“By the following vote, a shareholder proposal requesting a report on risks of supporting abortion was not approved:”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. at the 2023-05-01 meeting.

“By the following vote, a shareholder proposal requesting to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents was not approved:”

ELI LILLY & Co shareholders rejected Shareholder proposal to eliminate the supermajority voting requirements in the Articles. at the 2023-05-01 meeting.

“By the following vote, a shareholder proposal to eliminate the supermajority voting requirements in the Articles was not approved:”

ELI LILLY & Co shareholders rejected Shareholder proposal requesting publication of an annual report disclosing lobbying activities. at the 2023-05-01 meeting.

“By the following vote, a shareholder proposal requesting publication of an annual report disclosing lobbying activities was not approved:”

ELI LILLY & Co shareholders rejected Proposal to amend the Articles to eliminate supermajority voting provisions. at the 2023-05-01 meeting.

“The proposal to amend the Articles to eliminate supermajority voting provisions did not receive the required vote of 80% of outstanding shares.”

ELI LILLY & Co shareholders rejected Proposal to amend the Articles of Incorporation to eliminate the classified board structure. at the 2023-05-01 meeting.

“The proposal to amend the Company's Articles of Incorporation (the "Articles") to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares.”

ELI LILLY & Co shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent auditor for 2023. at the 2023-05-01 meeting.

“The appointment of Ernst & Young LLP as the Company's independent auditor for 2023 was ratified by the following shareholder vote:”

ELI LILLY & Co shareholders approved Advisory vote on the frequency of future advisory votes on named executive officer compensation. at the 2023-05-01 meeting.

“By the following vote, the shareholders approved, on an advisory basis, the frequency of future advisory votes on named executive officer compensation: 1 Year 2 Years 3 Years Abstain 767,074,001 930,914 7,654,785 1,176,641”

ELI LILLY & Co shareholders approved Advisory vote to approve the compensation paid to the Company's named executive officers. at the 2023-05-01 meeting.

“By the following vote, the shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers:”

ELI LILLY & Co shareholders approved Election of four nominees for director to serve three-year terms ending at the Company's annual meeting of shareholders in 2026. at the 2023-05-01 meeting.

“The four nominees for director were elected to serve three-year terms ending at the Company's annual meeting of shareholders in 2026, as follows:”

ELI LILLY & Co reported First Quarter 2023 results: revenue $6,960.0, net income $1,344.9, EPS $1.49. Guidance raised.

“Financial Results $ in millions, except per share data First Quarter 2023 2022 % Change Revenue $6,960.0 $7,810.0 (11)% Net Income – Reported 1,344.9 1,902.9 (29)% EPS – Reported 1.49 2.10 (29)% Net Income – Non-GAAP 1,463.9 2,372.8 (38)% EPS – Non-GAAP 1.62 2.62 (38)%”

ELI LILLY & Co reported financial results for the quarter and year ended December 31, 2022.

“Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 2, 2023, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2022.”

ELI LILLY & Co reported FY2022 results: revenue $28.5 to $29.0 billion, EPS $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis. Guidance reaffirmed.

“IPR&D or development milestone charges incurred during Q4 2022. 2 The company reaffirmed its 2022 financial guidance, as set forth in the following table: 2022 Guidance Revenue $28.5 to $29.0 billion Gross Margin % of Revenue (reported) Approx. 76% Gross Margin % of Revenue (non-GAAP) Approx. 78% Marketing, Selling & Administrative $6.4 to $6.6 billion”

ELI LILLY & Co reported FY2023 results: revenue $30.3 billion to $30.8 billion, EPS $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.

“2023 revenue expected to be between $30.3 billion and $30.8 billion, driven by key growth products. • 2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.”

ELI LILLY & Co reported the third quarter of 2022 results: revenue $6,941.6, net income 1,451.7, EPS $1.61.

“other important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Third Quarter % 2022 2021 Change Revenue $6,941.6 $6,772.8 2% Net Income – Reported 1,451.7 1,110.1 31% EPS – Reported 1.61 1.22 32% Net Income – Non-GAAP 1,789.2 1,614.2 11% EPS – Non-GAAP 1.98 1.77 12% A discussion of the”

Dr. Mary Lynne Hedley was elected as Director at ELI LILLY & Co.

“On May 2, 2022, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Dr. Mary Lynne Hedley as a new member of the class of 2025, effective May 15, 2022.”

Carolyn R. Bertozzi resigned as Director at ELI LILLY & Co.

“In connection with the Company’s entry into the collaboration and licensing agreement, Carolyn R. Bertozzi, academic founder of Lycia, resigned from the Company’s Board of Directors, effective August 23, 2021.”

Alfonso Zulueta departed as Senior Vice President and President, Lilly International at ELI LILLY & Co.

“On August 11, 2021, Alfonso Zulueta, Senior Vice President and President, Lilly International, of Eli Lilly and Company (the “Company”) notified the Board of Directors of the Company of his intent to retire from his position with the Company effective as of December 26, 2021.”